Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
Sponsor: Mclean Hospital
Summary
Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.
Key Details
Gender
FEMALE
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-02-27
Completion Date
2026-06
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
Cannabidiol
Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
Placebo
An active placebo containing supplemental terpenes matched to the high-CBD product.
Locations (1)
McLean Hospital
Belmont, Massachusetts, United States